Integral Molecular's Out-licensed Bispecific Antibody Enters Clinical Trial for Treating Solid Tumors
PHILADELPHIA, March 6, 2025 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery against membrane proteins, is pleased to announce that its out-licensed anti-Claudin 6 (CLDN6) bispecific antibody, CTIM-76, has been dosed in the first patient in a Phase 1 clinical trial by its licensing partner, Context Therapeutics Inc. This milestone is part of a Phase 1 dose escalation and expansion trial enrolling patients with advanced or metastatic ovarian, endometrial, and testicular cancers.
CLDN6 is a structurally complex protein that is expressed in multiple cancers but absent from healthy tissue, making it an attractive drug target. However, targeting CLDN6 is challenging because numerous related proteins are present in healthy tissues.
Using their MPS Antibody Discovery platform, Integral Molecular isolated a lead molecule targeting a unique CLDN6 epitope to deliver potential best-in-class specificity compared with other molecules undergoing clinical development. Under a licensing agreement, Context Therapeutics Inc. is leading clinical development of CTIM-76, following the successful completion of IND-enabling studies.
CTIM-76 was generated using Integral Molecular's proprietary technologies for discovering therapeutics against challenging targets:
- MPS Antibody Discovery platform tailored to produce robust immune responses even against the most complex proteins and rare epitopes
- Bispecific antibody engineering strategies that assess numerous bispecific antibody stoichiometries and formats in vitro and in vivo
- Selection for exquisite specificity using Integral Molecular's Membrane Proteome Array™ that screens biologics for reactivity against 6,000 native membrane proteins
"Our antibody discovery platform continues to advance untapped targets across oncology, autoimmune diseases, and other therapeutic areas to discover breakthrough treatments for patients," said Joseph Rucker, PhD, Vice President of R&D at Integral Molecular. "We are proud to work with partners like Context Therapeutics who are bringing novel therapeutics to the clinic."
Learn more about Integral Molecular's pipeline of therapeutic antibody assets available for licensing
About Integral Molecular
Integral Molecular (integralmolecular.com) is the industry leader in creating transformative technologies that advance the discovery of therapeutics against difficult protein targets. With 20+ years of experience focused on membrane proteins, viruses, and antibodies, Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 600 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses.
Follow Integral Molecular on LinkedIn
Press Contact
Integral Molecular
Soma Banik, PhD, Director of Public Relations
215-966-6061
View original content to download multimedia:https://www.prnewswire.com/news-releases/integral-moleculars-out-licensed-bispecific-antibody-enters-clinical-trial-for-treating-solid-tumors-302393696.html
SOURCE Integral Molecular